$FBDS
Fuss Brands Corp.

2024 Q3 Form 10-Q Financial Statement

#000182912624006140 Filed on September 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $45.09K
YoY Change -60.78%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $45.09K
YoY Change -60.78%
Operating Profit -$45.09K
YoY Change -60.78%
Interest Expense $1.295K
YoY Change 50.76%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$46.38K
YoY Change -59.95%
Income Tax
% Of Pretax Income
Net Earnings -$46.38K
YoY Change -59.95%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 19.09M shares
Diluted Shares Outstanding 19.09M shares

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.010K
YoY Change -60.88%
Cash & Equivalents $9.007K
Short-Term Investments
Other Short-Term Assets $227.7K
YoY Change 77.73%
Inventory
Prepaid Expenses $227.7K
Receivables
Other Receivables
Total Short-Term Assets $236.7K
YoY Change 56.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $236.7K
Total Long-Term Assets $2.00
Total Assets $236.7K
YoY Change 56.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.01K
YoY Change -60.64%
Accrued Expenses $160.7K
YoY Change 42.41%
Deferred Revenue
YoY Change
Short-Term Debt $483.7K
YoY Change 391.64%
Long-Term Debt Due $50.00K
YoY Change 0.0%
Total Short-Term Liabilities $895.1K
YoY Change 95.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $895.1K
Total Long-Term Liabilities $0.00
Total Liabilities $895.1K
YoY Change 95.75%
SHAREHOLDERS EQUITY
Retained Earnings -$15.41M
YoY Change 22.88%
Common Stock $19.09K
YoY Change 23.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$658.4K
YoY Change
Total Liabilities & Shareholders Equity $236.7K
YoY Change 56.61%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$46.38K
YoY Change -59.95%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$137.7K
YoY Change 258.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 139.7K
YoY Change 179.38%
NET CHANGE
Cash From Operating Activities -137.7K
Cash From Investing Activities
Cash From Financing Activities 139.7K
Net Change In Cash 1.980K
YoY Change -82.98%
FREE CASH FLOW
Cash From Operating Activities -$137.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156978 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
50000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
50000 usd
CY2024Q3 fbds Notes Payable Related Party
NotesPayableRelatedParty
483676 usd
CY2023Q4 fbds Notes Payable Related Party
NotesPayableRelatedParty
98381 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
895069 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
588007 usd
CY2024Q3 us-gaap Liabilities
Liabilities
895070 usd
CY2023Q4 us-gaap Liabilities
Liabilities
588007 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
1584 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
834 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
361825 usd
us-gaap Operating Expenses
OperatingExpenses
361825 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-361825 usd
us-gaap Interest Expense
InterestExpense
859 usd
us-gaap Profit Loss
ProfitLoss
-362684 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000926844
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Revenues
Revenues
usd
CY2023Q3 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
fbds Convertible Notes
ConvertibleNotes
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-07-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34808
dei Entity Registrant Name
EntityRegistrantName
FUSS BRANDS CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-1343424
dei Entity Address Address Line1
EntityAddressAddressLine1
80 Broad Street
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10004
dei City Area Code
CityAreaCode
917
dei Local Phone Number
LocalPhoneNumber
720-3366
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19090078 shares
CY2024Q3 us-gaap Cash
Cash
9007 usd
CY2023Q4 us-gaap Cash
Cash
9448 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
227655 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
129917 usd
CY2024Q3 us-gaap Assets
Assets
236662 usd
CY2023Q4 us-gaap Assets
Assets
139364 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
24008 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
105991 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
160728 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
19090 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
19090 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14803143 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12287167 usd
CY2024Q3 fbds Discount On Common Stock
DiscountOnCommonStock
-75889 usd
CY2023Q4 fbds Discount On Common Stock
DiscountOnCommonStock
-75889 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15406336 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12679846 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-658408 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-448643 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
236662 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139364 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45089 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
114968 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2722695 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
45089 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
114968 usd
us-gaap Operating Expenses
OperatingExpenses
2722695 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-45089 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-114968 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2722695 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
1295 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
859 usd
us-gaap Interest Expense
InterestExpense
3795 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46384 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-115827 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2726490 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-362684 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-46384 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-115827 usd
us-gaap Profit Loss
ProfitLoss
-2726490 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19090078 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19090078 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15445078 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15445078 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19090078 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19090078 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15445078 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15445078 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63887 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-68325 usd
CY2023Q1 fbds Private Placement Of Common Shares
PrivatePlacementOfCommonShares
23525 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-108688 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
96917 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-178532 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-190302 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-115827 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-306130 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-448643 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-46259 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-494903 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2516727 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2633846 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-612021 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-46384 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-658408 usd
us-gaap Profit Loss
ProfitLoss
-2726490 usd
us-gaap Profit Loss
ProfitLoss
-362684 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2516727 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
96917 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
97739 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
128087 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-81983 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
59944 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
135018 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3750 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112859 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-385735 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86033 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
23525 usd
fbds Convertible Notes
ConvertibleNotes
50000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
385295 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
385295 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73525 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-441 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12508 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9448 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35539 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9007 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23031 usd
CY2023Q1 fbds Purchase Amount
PurchaseAmount
925000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2024Q3 fbds Negative Working Capital
NegativeWorkingCapital
658407 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15406336 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zDn0zdMtg1oc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zJGHOGuhstI9">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amount of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 26
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
450060 usd
CY2024Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
274402 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
227655 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
129917 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9007 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9448 usd
fbds Funding Amount
FundingAmount
385295 usd
CY2024Q3 fbds Notes Payable Related Party
NotesPayableRelatedParty
483676 usd
CY2023Q4 fbds Notes Payable Related Party
NotesPayableRelatedParty
98381 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 26
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50593 usd
CY2022Q3 fbds Discount On Common Stock
DiscountOnCommonStock
75889 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23525 usd
CY2023Q2 us-gaap Share Price
SharePrice
0.5701
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
96917 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Conversion Of Stock Description
ConversionOfStockDescription
one thousand (1,000) fully paid and nonassessable shares of Common Stock (the “Series A-1 Conversion Ratio”).
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2516727 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1584254 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1584254 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
834254 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
834254 shares
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
0 usd
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
0 usd

Files In Submission

Name View Source Status
0001829126-24-006140-index-headers.html Edgar Link pending
0001829126-24-006140-index.html Edgar Link pending
0001829126-24-006140.txt Edgar Link pending
0001829126-24-006140-xbrl.zip Edgar Link pending
fbds-20240731.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fussbrands_10q.htm Edgar Link pending
fussbrands_ex31-1.htm Edgar Link pending
fussbrands_ex32-1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
fbds-20240731_cal.xml Edgar Link unprocessable
fbds-20240731_def.xml Edgar Link unprocessable
fbds-20240731_pre.xml Edgar Link unprocessable
fussbrands_10q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fbds-20240731_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable